Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial
- PMID: 33857410
- DOI: 10.1016/S1470-2045(21)00125-X
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial
Conflict of interest statement
AI reports personal fees and honoraria for lectures from Bristol Myers Squibb and Merck Sharp & Dohme and advisory board for Novartis. FG reports honoraria for lectures and advisory board for Novartis, Pfizer, Merck, Pierre Fabre, and Boehringer Ingelheim; honoraria for lectures from Amgen, AstraZeneca, and Roche; and research funding, honoraria for lectures, and advisory board from Bristol Myers Squibb.
Comment on
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857412 Clinical Trial.
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857414 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
